ROCK2 Part 2: Sam Wak­sal’s Gravi­ton pairs up with Ovid Ther­a­peu­tics in rare CNS in­di­ca­tions

Ovid Ther­a­peu­tics is tap­ping in­to Sam Wak­sal’s Cor­morant-backed Gravi­ton Bio­science to de­vel­op mul­ti­ple sec­ond-gen­er­a­tion ROCK2 in­hibitors to fol­low Wak­sal’s first go-around with Rezurock at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER